New Protein That Can Fight Aggressive Breast Cancer Discovered

A protein has been identified that can improve the survival rate of patients with metastatic breast cancer. According to researchers at University of Texas Southwestern Medical Center in the US, this protein could be a target for future therapies.

Metastatic breast cancer is cancer that has spread to other sites in the body, and the vast majority of breast cancer deaths occur in patients in whom the cancer has metastasised.

Breast Cancer - Causes, Risks, Symptoms, Diagnosis, Staging, Treatment, Prevention & Prognosis
Breast cancer is a cancer that affects the breasts or mammary glands. Early detection and lifestyle changes help in controlling breast cancer.

‘Researchers have identified a protein that is strongly linked with metastatic breast cancer, which can also be a target for future therapies.’

Tweet it Now

The findings, published in the Journal of Clinical Investigation, suggest that high levels of the protein ZMYND8 could be correlated with poor survival in breast cancer patients.

Previous research had shown that breast cancer cells that are more aggressive in an oxygen-deprived, or hypoxic, environment.

A protein family called hypoxia-inducible factor (HIF) controls responses to hypoxia, switching on pathways that lead to cancer cell growth and spread.

Breast Cancer - Prevention and Management with Lifestyle Changes
Lifestyle choices may or may not cause breast cancer but healthy lifestyle changes can open up avenues beyond breast cancer. Good habits will allow one to fight breast cancer and to live with dignity.

"Our research shows that ZMYND8 is a regulator that activates hundreds of HIF-dependent oncogenes in breast cancer cells," said Weibo Luo, Assistant Professor at University of Texas Southwestern Medical Center in the US.

Research with a mouse model of breast cancer showed that depletion of the protein blocks the growth of new blood vessels in tumours and leads to breast cancer cell death.

FDA Approves Abemaciclib to Treat Women With Certain Breast Cancers
Abemaciclib was approved by FDA for treating postmenopausal women with certain types of breast cancer in combination with aromatase inhibitors in whom cancer has progressed despite the endocrine therapy.

This work "reveals a possible molecular target for diagnosis and treatment of aggressive disease", Luo said.

Reducing the Chances of Death from Breast Cancer With a Double Mastectomy
Undergoing a double mastectomy reduces the risk of developing breast cancer and dying in women who have BRCA1 mutations.

Source-IANS